Tag: Novo Notrdisk

August 16, 2017 Off

Novo Nordisk trial shows superior glucose control and weight loss with semaglutide compared to dulaglutide

By Dino Mustafić

Novo Nordisk’s SUSTAIN 7 trial results, announced on Wednesday, showed that treating people with type 2 diabetes with once-weekly semaglutide reduced HbA1c and body weight compared to treatment with dulaglutide. The trial tested the 0.5 mg semaglutide compared with 0.75 dulaglutide, and 1.0 mg semaglutide compared with 1.5 mg dulaglutide, when added to metformin.